https://www.selleckchem.com/pr....oducts/stat-in-1.htm
With the expanding use of immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer, the occurrence of acquired resistance (AR) has gradually emerged. However, the progression patterns and survival of patients with AR to ICIs are still unknown. To explore the characteristics and prognosis of AR after ICI therapy in patients with advanced GI cancer. This cohort study screened patients with advanced GI cancer treated with ICIs between January 14, 2016, and December 31, 2020, at Peking University Cancer Hospital. Initial respon